Orlando, FL, Aug. 07, 2018 (GLOBE NEWSWIRE) --
CEOLive.TV , a news organization that highlights leading CEOs, companies, and industry experts for investors, today released its second video interview [ https://ceolive.tv/precision-therapeutics-aip...an-patent/ ] with Dr. Carl Schwartz, CEO of Precision Therapeutics Inc (NASDAQ: AIPT ).
In a previous March 2018 discussion with CEOLive.TV’s Mike Elliott, Schwartz explained that Precision Therapeutics had the potential to revolutionize the treatment of cancer through personalized medicine, while also becoming a leader in the safe disposal of medical waste fluid during hospital procedures.
Now, in the new interview, which can be viewed at https://ceolive.tv/precision-therapeutics-aip...an-patent/ , Schwartz tells Elliott that the company is rapidly moving forward to turn its huge promise into reality. “Everyone should keep their eye on us,” he says.
Through its near-term merger with Helomics , for example, Precision Therapeutics now has access to nearly 150,000 individual tumors, along with key information on how those tumors respond to drugs, plus an artificial intelligence platform (the D-CHIP) for analyzing the data. In a recent interview with Health Media Now , Gerald Vardzel, President and CEO of Helomics, describes how this is ushering in a new era of individualized cancer treatment.
In addition, Precision Therapeutics’ wholly owned subsidiary TumorGenesis is the first company to develop a method of growing human tumors in the lab, where the “tumor thinks it is still in the body,” Schwartz says. That makes it possible to test cocktails of drugs against individual tumors to find the right drugs for fighting an individual’s unique cancer.
Precision Therapeutics’ unique capabilities have become even more important now that Congress has passed the so-called Right To Try law , which allows terminally ill patients to try experimental drugs. “We uniquely positioned to work with that,” says Schwartz. “We can take the tumor, test it outside the body, see what works and then use it to help the patient.”
The company is also making considerable progress with its innovative Streamway automated fluid waste disposal system, which is sold through its Skyline subsidiary. The Streamway system is the only technology that collects body fluids and other medical waste and sends the waste directly to the drain, virtually eliminating the chances of hospital workers getting infected by viruses or bacteria in the body fluids. Skyline has just gotten strong patent protection in 38 European countries, and is developing a sales organization across Europe, Canada, the U.S., and other countries, says Schwartz. Moreover, it will begin offering a third generation Streamway system later this year that is smaller, more efficient, and more versatile.
Overall, it’s a very impressive track record. “It’s a great story for investors to look at,” says Elliott.
About Precision Therapeutics Inc.
Precision Therapeutics ( AIPT ) operates in two business areas: first, applying artificial intelligence to personalized medicine and drug discovery to provide personalized medicine solutions for patients and clinicians as well as clients in the pharmaceutical, diagnostic, and biotech industries, and second, production of the FDA-approved STREAMWAY® System for automated, direct-to-drain medical fluid disposal. For additional information, please visit www.precisiontherapeutics.com .
About CEOLIVE Media Group
CEOLIVE Media Group offers extensive, in-depth coverage of U.S publicly traded companies and their management teams. Our exclusive interviews and investor profiles have been viewed by millions of investors and featured on thousands of investor media networks globally. Although we cover companies from multiple sectors and of all sizes our focus is on emerging opportunities in the biotech, technology and legal Cannabis space.
For more information and to follow our coverage of exciting opportunities please visit CEOLIVE.tv.
Safe Harbor Act: This release includes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involves risks and uncertainties including, but not limited to, the impact of competitive products, the ability to meet customer demand, the ability to manage growth, acquisitions of technology, equipment, or human resources, the effect of economic business conditions and the ability to attract and retain skilled personnel. The Company is not obligated to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.
Mike Elliot CEOLive Media Group Phone: (813) 421-1701 newsdesk@ceolive.tv
